BioStem Technologies, Inc.: a holder discloses a stake of more than 5% (Schedule 13G)

BioStem Technologies, Inc. received a Schedule 13G filing disclosing that an investor holds a stake exceeding 5% of the company. The filing, SEC accession 0001213900-26-118034, was submitted under the beneficial ownership reporting rules that apply to passive investors. The disclosure signals that a single holder has accumulated a meaningful position in the regenerative medicine company. The filing does not specify the exact ownership percentage or the identity of the holder in the headline summary. Investors will watch for further detail on the holder's identity and stake size, and for any subsequent 13G amendments that reveal whether the position is being increased or reduced.